An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)

References

• Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171–232.18315614
   PubMed Web of Science ®Google Scholar
• Friedman KD, Rodgers GM. Inherited coagulation disorders In: Greer JP, Foerster J, Rodgers GM, editors. Wintrobe’s Clinical Haematology. 12th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:1379–1424.
   Google Scholar
• Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand’s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica. 2003;88(1):94–108.12551832
   PubMed Web of Science ®Google Scholar
• Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1994;71(4):520–525. doi:10.1055/s-0038-16424718052974
   PubMed Web of Science ®Google Scholar
• Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4(10):2103–2114. doi:10.1111/j.1538-7836.2006.02146.x16889557
   PubMed Web of Science ®Google Scholar
• Leebeek FW, Eikenboom JC. Von Willebrand’s disease. N Engl J Med. 2016;375(21):2067–2080. doi:10.1056/NEJMra160156127959741
   PubMed Web of Science ®Google Scholar
• Mannucci PM. How I treat patients with von Willebrand disease. Blood. 2001;97(7):1915–1919. doi:10.1182/blood.V97.7.191511264151
   PubMed Web of Science ®Google Scholar
• Lissitchkov TJ, Buevich E, Kuliczkowski K, et al. Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study). Blood Coagul Fibrinolysis. 2017;28(2):152–162.27203734
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European Public Assessment Report (EPAR). Voncento: human coagulation factor VIII/von Willebrand factor; 2013 Available from: https://www.ema.europa.eu/en/documents/assessment-report/voncento-epar-public-assessment-report_en.pdf. Accessed 318, 2020.
   Google Scholar
• Auerswald G, Djambas Khayat C, Stasyshyn O, et al. Pharmacokinetics, efficacy and safety of a plasma-derived VWF/FVIII concentrate (Formulation V) in pediatric patients with von Willebrand disease (SWIFTLY-VWD study). J Blood Med. 2020;11:213–225. doi:10.2147/JBM.S23678932607039
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Extension study of Biostate in subjects with Von Willebrand Disease (NCT01224808); 2019 Available from: https://clinicaltrials.gov/ct2/show/NCT01224808. Accessed 318, 2020.
   Google Scholar
• European Medicines Agency (EMA). Guideline on the clinical investigation of human plasma derived von Willebrand factor products (CPMP/BPWG/220/02); 2010 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500067126.pdf. Accessed 318, 2020.
   Google Scholar
• European Medicines Agency (EMA). Guideline on the core SPC for human plasma-derived and recombinant coagulation factor VIII products (CPMP/BPWG/1619/1999); 2007 Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-spc-human-plasma-derived-recombinant-coagulation-factor-viii-products-revision_en.pdf. Accessed 318, 2020.
   Google Scholar
• Windyga J, von Depka-Prondzinski M; European Wilate Study Group. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost. 2011;105(6):1072–1079. doi:10.1160/TH10-10-063121437358
   PubMed Web of Science ®Google Scholar
• Octapharma. WILATE® Summary of Product Characteristics; 2020 Available from: https://www.medicines.org.uk/emc/product/2873/smpc. Accessed 813, 2020.
   Google Scholar
• LFB Biopharmaceuticals. WILLFACT® Summary of Product Characteristics; 2016 Available from: https://www.medicines.org.uk/emc/medicine/29947. Accessed 318, 2020.
   Google Scholar
• Miesbach W, Krekeler S, Wolf Z, Seifried E. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study. Thromb Res. 2015;135(3):479–484. doi:10.1016/j.thromres.2014.12.01725595881
   PubMed Web of Science ®Google Scholar
• Berntorp E, Windyga J. Treatment and prevention of acute bleedings in von Willebrand disease–efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia. 2009;15(1):122–130. doi:10.1111/j.1365-2516.2008.01901.x19149848
   PubMed Web of Science ®Google Scholar
• Khair K, Batty P, Riat R, et al. Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience. Haemophilia. 2015;21(1):e44–e50. doi:10.1111/hae.1249725112927
   PubMed Web of Science ®Google Scholar
• Goudemand J, Bridey F, Claeyssens S, et al. Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: results from a prospective observational post-marketing study. J Thromb Haemost. 2020;18(8):1922–1933. doi:10.1111/jth.1492832445594
   PubMed Web of Science ®Google Scholar
• CSL Behring. VONCENTO® Summary of Product Characteristics; 2019 Available from: https://www.medicines.org.uk/emc/medicine/28757. Accessed 318, 2020.
   Google Scholar
• Coppola A, Franchini M, Makris M, Santagostino E, Di Minno G, Mannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia. 2012;18(3):e173–e187. doi:10.1111/j.1365-2516.2012.02758.x22335611
   PubMed Web of Science ®Google Scholar
• Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345(8943):152–155. doi:10.1016/S0140-6736(95)90166-37823669
   PubMed Web of Science ®Google Scholar
• Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb Haemost. 2002;88(3):387–388. doi:10.1055/s-0037-161322712353065
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost. 2002;88(3):378–379. doi:10.1055/s-0037-161322512353063
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Chediak J, Hanna W, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002;99(2):450–456. doi:10.1182/blood.V99.2.45011781224
   PubMed Web of Science ®Google Scholar
• Dunkley S, Baker RI, Pidcock M, et al. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand’s disease: a prospective multi-centre study. Haemophilia. 2010;16(4):615–624.20331755
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Lloyd J, Rowell J, et al. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. Thromb Haemost. 2007;97(6):922–930. doi:10.1160/TH06-09-049517549293
   PubMed Web of Science ®Google Scholar
• Howman R, Barnes C, Curtin J, et al. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review. Haemophilia. 2011;17(3):463–469. doi:10.1111/j.1365-2516.2010.02445.x21118340
   PubMed Web of Science ®Google Scholar
• Shortt J, Dunkley S, Rickard K, Baker R, Street A. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures. Haemophilia. 2007;13(2):144–148. doi:10.1111/j.1365-2516.2006.01430.x17286766
   PubMed Web of Science ®Google Scholar
• Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost. 2007;5(6):1115–1124. doi:10.1111/j.1538-7836.2007.02562.x17403090
   PubMed Web of Science ®Google Scholar